Challenges for Immunotherapy in Multiple Myeloma: Bone Marrow Microenvironment-Mediated Immune Suppression and Immune Resistance

by Lisa C. Holthof, Tuna Mutis
Published 2020-04-01

Characterization of the Toll-like receptor expression profile in human multiple myeloma cells.

by Jahangir Abdi, Tuna Mutis, Johan Garssen, Frank Redegeld
Published 2013-01-01

Toll-like receptor (TLR)-1/2 triggering of multiple myeloma cells modulates their adhesion to bone marrow stromal cells and enhances bortezomib-induced apoptosis.

by Jahangir Abdi, Tuna Mutis, Johan Garssen, Frank A Redegeld
Published 2014-01-01

The Connection Between Minor H Antigens and Neoantigens and the Missing Link in Their Prediction

by Tuna Mutis, Anastasia Xagara, Anastasia Xagara, Robbert M. Spaapen, Robbert M. Spaapen
Published 2020-06-01

Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies

by Hilma J. van der Horst, Inger S. Nijhof, Tuna Mutis, Martine E. D. Chamuleau
Published 2020-10-01

Targeted Therapy With Immunoconjugates for Multiple Myeloma

by Wassilis S. C. Bruins, Sonja Zweegman, Tuna Mutis, Niels W. C. J. van de Donk
Published 2020-06-01

Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment

by Jort J. van der Schans, Niels W. C. J. van de Donk, Tuna Mutis
Published 2020-08-01

Immunotherapy in myeloma: how far have we come?

by Laurens E. Franssen, Tuna Mutis, Henk M. Lokhorst, Niels W. C. J. van de Donk
Published 2019-01-01

Impact of MYC on Anti-Tumor Immune Responses in Aggressive B Cell Non-Hodgkin Lymphomas: Consequences for Cancer Immunotherapy

by A. Vera de Jonge, Tuna Mutis, Margaretha G. M. Roemer, Blanca Scheijen, Martine E. D. Chamuleau
Published 2020-10-01

Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design.

by Esther Drent, Renée Poels, Manon J Mulders, Niels W C J van de Donk, Maria Themeli, Henk M Lokhorst, Tuna Mutis
Published 2018-01-01

Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies

by Christie P. M. Verkleij, Amy Jhatakia, Marloes E. C. Broekmans, Kristine A. Frerichs, Sonja Zweegman, Tuna Mutis, Natalie A. Bezman, Niels W. C. J. van de Donk
Published 2020-12-01

Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma

by Renée Poels, Esther Drent, Roeland Lameris, Afroditi Katsarou, Maria Themeli, Hans J. van der Vliet, Tanja D. de Gruijl, Niels W.C.J. van de Donk, Tuna Mutis
Published 2021-01-01

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients

by Kristine A. Frerichs, Christie P. M. Verkleij, Meletios A. Dimopoulos, Jhon A. Marin Soto, Sonja Zweegman, Mary H. Young, Kathryn J. Newhall, Tuna Mutis, Niels W. C. J. van de Donk
Published 2021-05-01

Potent Preclinical Efficacy of DuoHexaBody-CD37 in B-Cell Malignancies

by Hilma J. van der Horst, Simone C. Oostindie, Saskia. A. G. M. Cillessen, Anne T. Gelderloos, Marije B. Overdijk, Inger. S. Nijhof, Sonja Zweegman, Martine E. D. Chamuleau, Esther C. W. Breij, Tuna Mutis
Published 2021-01-01

Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant

by Lisa C. Holthof, Arwen Stikvoort, Hilma J. van der Horst, Anne T. Gelderloos, Renée Poels, Fengzhi Li, Richard W. J. Groen, Sonja Zweegman, Niels W. C. J. van de Donk, Michael O’Dwyer, Tuna Mutis
Published 2021-05-01

CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an “Off the Shelf” Therapy for Multiple Myeloma

by Arwen Stikvoort, Jort van der Schans, Subhashis Sarkar, Renée Poels, Ruud Ruiter, Jyoti Naik, Huipin Yuan, Joost D. de Bruijn, Niels W. C. J. van de Donk, Sonja Zweegman, Maria Themeli, Richard Groen, Michael O’Dwyer, Tuna Mutis
Published 2021-07-01

RhoB Mediates Phosphoantigen Recognition by Vγ9Vδ2 T Cell Receptor

by Zsolt Sebestyen, Wouter Scheper, Anna Vyborova, Siyi Gu, Zuzana Rychnavska, Marleen Schiffler, Astrid Cleven, Coraline Chéneau, Martje van Noorden, Cassie-Marie Peigné, Daniel Olive, Robert Jan Lebbink, Rimke Oostvogels, Tuna Mutis, Gerrit Jan Schuurhuis, Erin J. Adams, Emmanuel Scotet, Jürgen Kuball
Published 2016-05-01

Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment

by Hilma J. van der Horst, A. Vera de Jonge, Ida H. Hiemstra, Anne T. Gelderloos, Daniella R. A. I. Berry, Nathalie J. Hijmering, Hendrik F. van Essen, Daphne de Jong, Martine E. D. Chamuleau, Sonja Zweegman, Esther C. W. Breij, Margaretha G. M. Roemer, Tuna Mutis
Published 2021-02-01

Complete Tumor Regression by Liposomal Bortezomib in a Humanized Mouse Model of Multiple Myeloma

by Anil K. Deshantri, Marcel H.A.M. Fens, Ruud W.J. Ruiter, Josbert M. Metselaar, Gert Storm, Sanjay N. Mandhane, Gerard H.M. Graat, Eef G.W. Lentjes, Huipin Yuan, Joost D. de Bruijn, Tuna Mutis, Anton C.M. Martens, Richard W.J. Groen, Raymond M. Schiffelers
Published 2020-10-01